Inotek initiates enrollment for Phase I glaucoma trial

The initial study will evaluate the safety, tolerability, and the potential of INO-8875 to lower intraocular pressure (IOP) in glaucoma patients. Glaucoma patients typically have elevated levels of IOP which can damage the optic nerve of the eye and lead to partial or complete loss of vision.

In March 2008, Inotek received approval from the FDA to advance INO-8875 into clinical trials.

Rudolf Baumgartner, chief medical officer of Inotek, said: “We are pleased that our clinical program in glaucoma is progressing and I am encouraged by the strength of our preclinical data supporting the potential role of Adenosine 1 receptor agonists in managing intraocular pressure.”